A recently unsealed complaint alleges that Forest Pharmaceuticals paid the lead research physician of a National Institute of Health (NIH) funded study of anti-depressants to fix the results in favor its drug, Celexa.  The whistleblower, a psychologist, co-wrote an article published in 2009 which alleged that the study’s results were biased in favor of Celexa and that the bias was the result of improper financial inducements.  The whistleblower challenged the study’s decision to use Celexa as the default test drug, despite it being the least prescribed anti-depressant at the time.  According to the complaint, prescriptions of Celexa and Forest’s generic anti-depressant Lexapro have increased since the study results were released.

Read the entire article, “Whistleblower Claims Forest Bribed Study’s Investigator to Favor Celexa”